ASPET

OCTOBER 20, 2023

This study aimed to evaluate the effects of cytochrome P450 3A4 (CYP3A4) gene polymorphism and drug interaction on the metabolism of blonanserin. Human recombinant CYP3A4 was prepared using the Bac-to-Bac baculovirus expression system.

Pharmacogenetics 100

Pharmacogenetics Drugs 100

ASPET

OCTOBER 12, 2023

Achieving adequate exposure of a therapeutic agent at the target is a critical determinant of efficacious chemotherapy. With this in mind, a major challenge in developing therapies for central nervous system (CNS) tumors is to overcome barriers to delivery, including the blood-brain barrier (BBB).

Pharmacogenetics 100

Pharmacogenetics Clinical Trials Treatment Therapies 100

ASPET

AUGUST 8, 2024

Lenacapavir (LEN), a long-acting injectable, is the first approved human immunodeficiency virus type 1 capsid inhibitor and one of a few FDA-approved drugs that exhibit atropisomerism.

Pharmacogenetics 100

Pharmacogenetics Pharmacokinetics FDA Approval Virus 100

ASPET

AUGUST 4, 2023

Neuroblastoma (NB) is a pediatric cancer with low survival rates in high-risk patients. 131 I-mIBG has emerged as a promising therapy for high-risk NB and kills tumor cells by radiation. Consequently, 131 I-mIBG tumor uptake and retention are major determinants for its therapeutic efficacy.

Pharmacogenetics 100

Pharmacogenetics Therapies Disease 100

ASPET

SEPTEMBER 16, 2024

Glioblastoma (GBM) is a disease of the whole brain, with infiltrative tumor cells protected by an intact BBB. GBM has a poor prognosis despite aggressive treatment, in part due to lack of adequate drug permeability at the BBB. Standard of care GBM therapies include radiation and cytotoxic chemotherapy that lead to DNA damage.

Pharmacogenetics 100

Pharmacogenetics DNA Treatment Pharmacokinetics 100

ASPET

MARCH 6, 2024

The organic anion transporting polypeptide (OATP) 2B1 (gene name SLCO2B1 ) is an uptake transporter that facilitates cellular accumulation of its substrates. In order to assess the in vivo relevance of the transporter, we applied SLCO2B1 +/+ knock-in and Slco2b1 -/- knock-out rats.

Protein Expression 100

Protein Expression Pharmacogenetics Treatment Drugs 100

ASPET

JUNE 10, 2024

Radiation therapy, a standard treatment option for many cancer patients, induces DNA double strand breaks (DSBs), leading to cell death. Ataxia telangiectasia mutated (ATM) kinase is a key regulator of DSB repair, and ATM inhibitors are being explored as radiosensitizers for various tumors, including primary and metastatic brain tumors.

Pharmacokinetics 100

Pharmacokinetics Pharmacogenetics Treatment DNA 100

The Open Targets Blog

NOVEMBER 30, 2023

Introducing pharmacogenetics data to the Platform This release introduces a new datasource to the Platform: the pharmacogenetics widget will incorporate data about the impact of human genetic variation on drug responses. You can find this data on the target and drug profile pages.

Pharmacogenetics 57

Pharmacogenetics Small Molecule Disease Drugs 57

ASPET

JANUARY 31, 2024

We recently showed that riboflavin is a selected substrate of BCRP over P-gp and demonstrated its prediction performance in preclinical DDI studies. The aim of this study was to investigate the suitability of riboflavin to assess BCRP inhibition in humans.

Pharmacogenetics 100

Pharmacogenetics Pharmacokinetics Drug Development Drugs 100

ASPET

NOVEMBER 17, 2023

Creatinine, a clinical marker for kidney function, is predominantly cleared by glomerular filtration, with active tubular secretion contributing to about 30% of its renal clearance.

Pharmacogenetics 100

Pharmacogenetics Pharmacokinetics Disease Drugs 100

ASPET

AUGUST 4, 2023

The natural product goldenseal is a clinical inhibitor of CYP3A activity, as evidenced by a 40-60% increase in midazolam AUC after coadministration with goldenseal. The predominant goldenseal alkaloids berberine and (-)-β-hydrastine were previously identified as time-dependent CYP3A inhibitors using human liver microsomes.

Pharmacokinetics 100

Pharmacokinetics Pharmacogenetics Production Drugs 100

The Pharma Data

OCTOBER 27, 2020

The system is a highly sensitive, cost-effective, mass spectrometry-based platform for high-throughput genetic analysis and is used globally in diverse research fields such as cancer profiling for solid tumors and liquid biopsies, inherited genetic disease testing, pharmacogenetics, agricultural genomics, and clinical research.

Pharmacogenetics 52

Pharmacogenetics Laboratories Clinical Research FDA 52

Alta Sciences

DECEMBER 31, 2024

In recent years, pharmacogenetics research has shown significant differences in the pharmacokinetics among Caucasians, African Americans, Hispanics, and Asians, or at individual levels by stratifying groups based on genetic analysis.

Therapies 52

Therapies Pharmacokinetics Pharmacogenetics Clinical Trials 52

The Pharma Data

OCTOBER 27, 2020

Collaborators today include Synlab, PathGroup (US), SRL Diagnostics (Asia), Fundación Jimenez Díaz, The Royal Marsden NHS Foundation Trust, Istituto Nazionale Tumori Regina Elena Roma and Diatech Pharmacogenetics (EU). Two global pharmaceutical clients are also piloting the technology.

Pharmacogenetics 40

Pharmacogenetics Laboratories Therapies Hospitals 40

The Open Targets Blog

MARCH 19, 2025

million GWAS credible sets identified are contextualised with results from gene burden analysis, pharmacogenetics or predominantly rare variation resources, drawing a richer map of the phenotypic effects of a broader range of variation. The more than 2.6

Disease 78

Disease Pharmacogenetics Research Drugs 78

The Open Targets Blog

MARCH 19, 2025

This includes L2G, rare disease clinical annotations, and pharmacogenetics annotations. This includes GWAS credible sets, molQTL credible sets, ClinVar clinical submissions, Uniprot curated variants, and pharmacogenetics annotations from PharmGKB. The Platform provides functional context for 6.5

Pharmacogenetics 62

Pharmacogenetics Disease Clinical Trials Trials 62